Clinical trial
A Pilot Study of Pivanex in Patients With Malignant Melanoma
NCT00087477 · Titan Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00087477 |
|---|---|
| Title | A Pilot Study of Pivanex in Patients With Malignant Melanoma |
| Official title | A Pilot Study of Pivanex, a Histone Deacetylase Inhibitor, in Patients With Malignant Melanoma |
| Lead sponsor | Titan Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | Pivanex |
| Enrollment | 14 |
| Start date | Jan 1, 2004 |
| Completion | Aug 1, 2004 |
| First posted | Jul 13, 2004 |
| Last update posted | Aug 30, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: